May 02, 2023 5:00pm EDT NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
Feb 14, 2023 4:10pm EST NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
Dec 21, 2022 8:00am EST NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022
Oct 21, 2022 8:00am EDT NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
Oct 14, 2022 4:05pm EDT NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
Aug 11, 2022 8:00am EDT NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
Jun 29, 2022 8:01am EDT NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
May 17, 2022 7:00am EDT NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution